I love Aussie Biotechs and one interesting comparison is to compare market caps to financials. Disclaimer, this is not apples for apples because different companies sit at different points along the Research and Development to Commercialisation pipeline but it may be interesting nonetheless. Below is a chart I have posted on another thread, here it it without comments attached and purely to see where this company sits on this comparison.
Original post is here. https://hotcopper.com.au/threads/ann-response-to-asx-price-query.6406559/page-10?post_id=57562064
All IMO DYOR
Ann: PME signs A$40M, 7 year deal with Novant Health, page-9
Add PME (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$135.21 |
Change
1.710(1.28%) |
Mkt cap ! $14.03B | |||
| Open | High | Low | Value | Volume |
| $134.03 | $135.52 | $133.55 | $8.151M | 60.48K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 15 | $135.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $135.24 | 27 | 4 |
View Market Depth
| Last trade - 13.04pm 19/06/2024 (20 minute delay) ? |
| PME (ASX) Chart |